Diagnostic accuracy of methods for the detection of BRCA1 and BRCA2 mutations: a systematic review
- 7 March 2007
- journal article
- review article
- Published by Springer Nature in European Journal of Human Genetics
- Vol. 15 (6) , 619-627
- https://doi.org/10.1038/sj.ejhg.5201806
Abstract
As sequence analysis for BRCA1 and BRCA2 mutations is both time- and cost-intensive, current strategies often include scanning techniques to identify fragments containing genetic sequence alterations. However, a systematic assessment of the diagnostic accuracy has been lacking so far. Here, we report on a systematic review to assess the internal and external validity of current scanning techniques. Inclusion criteria were: controlled design, investigators blinded, and tests suitable as a scanning tool for the whole genes BRCA1 and BRCA2. Outcome parameters were sensitivity, specificity, and positive and negative predictive values compared to direct sequencing. Out of 3816 publications, 10 studies reporting on 12 methods met our inclusion criteria. The internal and external validity of most of these studies was limited. Sensitivities were reported to be 100% for enzymatic mutation detection (EMD), multiple-dye cleavase fragment length polymorphism (MD-CFLP), fluorescence-based conformation-sensitive gel electrophoresis (F-CSGE), RNA-based sequencing, restriction endonuclease fingerprinting-single strand conformation polymorphism (REF-SSCP), stop codon (SC) assay, and denaturing high-performance liquid chromatography (DHPLC). Sensitivity was 50–96% for SSCP, 88–91% for two-dimensional gene scanning (TDGS), 76% for conformation-sensitive gel electrophoresis (CSGE), 75% for protein truncation test (PTT), and 58% for micronucleus test (MNT). Specificities close to 100% were reported, except for MNT. PTT and SC assay are only able to detect truncating mutations. Most studies were designed to introduce new experimental approaches or modifications of established methods and require further evaluation. F-CSGE, REF-SSCP, RNA-based sequencing, EMD, and MD-CFLP will need further evaluation before their use in a routine setting can be considered. SSCP, MNT, PTT, CSGE, and TDGS cannot be recommended because of their low sensitivity. DHPLC outperforms all other methods studied. However, none of the four studies evaluating DHPLC was performed on BRCA2.Keywords
This publication has 29 references indexed in Scilit:
- The 471delAAAG Mutation and C353T Polymorphism in the RNASEL Gene in Sporadic and Inherited Cancer in IsraelFamilial Cancer, 2006
- German populations with infrequent CHEK2*1100delC and minor associations with early-onset and familial breast cancerEuropean Journal Of Cancer, 2005
- Comparison of different melting temperature calculation methods for short DNA sequencesBioinformatics, 2004
- IMPACT OF GENE PATENTS ON THE COST-EFFECTIVE DELIVERY OF CARE: THE CASE OF BRCA1 GENETIC TESTINGInternational Journal of Technology Assessment in Health Care, 2003
- BRCA1 mutation screening using restriction endonuclase fingerprinting-single-strand conformation polymorphism in an automated capillary electrophoresis systemElectrophoresis, 2002
- Comparison of DNA- and RNA-Based Methods for Detection of TruncatingBRCA1 MutationsHuman Mutation, 2002
- A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genesBritish Journal of Cancer, 2002
- Detection of germline mutations in the BRCA1 gene by RNA-based sequencingHuman Mutation, 2001
- Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2Nature Genetics, 1996
- Identification of the breast cancer susceptibility gene BRCA2Nature, 1995